Back to top
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Frontline PLC (FRO) - free report >>
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Frontline PLC (FRO) - free report >>
Image: Bigstock
Top Ranked Momentum Stocks to Buy for October 9th
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, October 9th:
Frontline Ltd. (FRO - Free Report) : This shipping company has a Zacks Rank #1 (Strong Buy) and witnessed the Zacks Consensus Estimate for its current year earnings increasing 34.2% over the last 60 days.
Frontline Ltd. Price and Consensus
Frontline Ltd. price-consensus-chart | Frontline Ltd. Quote
Frontline’s shares gained 25% over the last one month more than S&P 500’s decline of 2.9%. The company possesses a Momentum Score of B.
Frontline Ltd. Price
Frontline Ltd. price | Frontline Ltd. Quote
Cesca Therapeutics Inc. (KOOL - Free Report) : This developer of cell-based therapeutics has a Zacks Rank #2 (Buy) and witnessed the Zacks Consensus Estimate for its current year earnings increasing 86% over the last 60 days.
Cesca Therapeutics Inc. Price and Consensus
Cesca Therapeutics Inc. price-consensus-chart | Cesca Therapeutics Inc. Quote
Cesca Therapeutics’ shares gained 49.5% over the last one month. The company possesses a Momentum Score of A.
Cesca Therapeutics Inc. Price
Cesca Therapeutics Inc. price | Cesca Therapeutics Inc. Quote
Cortexyme, Inc. : This pharmaceutical company has a Zacks Rank #2 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 14.2% over the last 60 days.
Cortexyme, Inc. Price and Consensus
Cortexyme, Inc. price-consensus-chart | Cortexyme, Inc. Quote
Cortexyme’s shares gained 10.8% over the last one month. The company possesses a Momentum Score of A.
Cortexyme, Inc. Price
Cortexyme, Inc. price | Cortexyme, Inc. Quote
Coeur Mining, Inc. (CDE - Free Report) : This mining company has a Zacks Rank #2 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 21.7% over the last 60 days.
Coeur Mining, Inc. Price and Consensus
Coeur Mining, Inc. price-consensus-chart | Coeur Mining, Inc. Quote
Coeur Mining’s shares gained 12.6% over the last one month. The company possesses a Momentum Score of B.
Coeur Mining, Inc. Price
Coeur Mining, Inc. price | Coeur Mining, Inc. Quote
See the full list of top ranked stocks here
Learn more about the Momentum score and how it is calculated here.
Today's Best Stocks from Zacks
Would you like to see the updated picks from our best market-beating strategies? From 2017 through 2018, while the S&P 500 gained +15.8%, five of our screens returned +38.0%, +61.3%, +61.6%, +68.1%, and +98.3%.
This outperformance has not just been a recent phenomenon. From 2000 – 2018, while the S&P averaged +4.8% per year, our top strategies averaged up to +56.2% per year.
See their latest picks free >>